Wendy's on Thursday rejected a $1.4 billion takeover offer from a group led by Nelson Peltz's Trian Fund Management. The bid, made at $7.35 per share in cash on Oct. 28, would have taken the burger chain private. The company's independent committee concluded that the proposal "substantially undervalues" Wendy's and does not reflect potential gains from its ongoing turnaround strategy. On the narrow question of price, that conclusion deserves respect.
The stakes for shareholders are easy to see. Wendy's same-store sales have declined for seven straight quarters, and the stock has lost about 60% of its value over the last three years. A buyout at a premium might look attractive to investors who have watched that decline. But the board's job is to protect the value of the company, not to accept the first offer that promises a quick exit from a difficult stretch. The committee's judgment that the bid was too low is a reasonable one to make.
The rejection also carries a risk. Wendy's has adopted a shareholder rights plan, commonly called a poison pill, with a one-year duration, and it said the Trian-led group turned down a standstill agreement that would have paused additional share purchases. A poison pill can be a legitimate defense against a hostile bid, but it can also entrench management and keep shareholders from deciding for themselves. Wendy's should explain clearly why it needs this tool now and when it plans to revisit it.
There is also a credibility question. Peltz has a long history with the company, including an activist campaign more than two decades ago and a 2008 deal in which his firm Triarc bought Wendy's for $2.3 billion. Peltz was named chairman emeritus in 2024 after 17 years on the board, and Trian executive Peter May and Bradley Peltz still sit on it. Those ties make the board's independence a fair thing to scrutinize, and the company should be prepared to show that the committee's review was rigorous.
Wendy's has said it is confident in Chief Executive Bob Wright's record in restaurant turnarounds, and the third-quarter earnings and revenue beat Wall Street's expectations. Those are encouraging signs. But a turnaround is only persuasive when the sales trend improves, and seven quarters of declines is hard to ignore. The board should set specific, public targets for same-store sales and explain how the strategy will close the gap. If it cannot, shareholders will have reason to ask whether the rejected offer was the better outcome after all.